Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
B-cell tailored versus standard ocrelizumab in relapsing-remitting multiple sclerosis
2021-004791-34Phase 4Active
- Sponsor
- Amsterdam University Medical Center
- Start
- Mar 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised trial of ocrelizumab in multiple sclerosis (MS) (2 arms), sponsored by Amsterdam University Medical Center. Primary endpoints: Confirmed relapse-free patients at 96 weeks and Patients without new or enlarging T2 MRI lesions at 96 weeks. Started Mar 2022; status: active.
02
Drugs
ocrelizumab
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on 2021-004791-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-004791-34.